GSK, AstraZeneca and J&J back $57M effort to springboard university drug research

John Carroll Three of the U.K.'s leading universities are joining hands with three of the world's biggest pharma giants to create a new translational medicine group aimed at ...

AstraZeneca chief chalks up milestones on his map to $45B

Tracy Staton AstraZeneca CEO Pascal Soriot summarizes his accomplishments at the U.K.-based pharma giant in two words–Lynparza and Tagrisso. FiercePharma News

AstraZeneca shrugs off pharma’s emerging markets slowdown, but Lilly’s suffering

Carly Helfand After Q2's glacial emerging markets growth, industry watchers wondered just how slow pharma could go in developing countries. As it turns out, they found a way to ...

AstraZeneca spending hundreds of millions in China, blueprints new R&D hub

John Carroll FierceBiotech News

AstraZeneca bets on the future of the ‘secretome,’ joining a $100M research effort

Damian Garde AstraZeneca, on the hunt for new drug targets, is teaming up with a Swedish research outfit to explore the potential of an emerging class of proteins, joining a $ 100 ...

UPDATED: AstraZeneca looks to bag Imbruvica rival in $5B-plus Acerta buyout: Report

John Carroll Four days after Acerta Pharma quietly posted some promising early-stage data on its Bruton's tyrosine kinase (Btk) inhibitor acalabrutinib, AstraZeneca has popped up ...

AstraZeneca walks back some of its immuno-oncology ambition

Damian Garde AstraZeneca, working to catch up with Merck and Bristol-Myers Squibb in the growing field of immuno-oncology, said its treatment is unlikely to win speedy approval in lung ...

AstraZeneca hikes full-year forecast as Nexium holds its own, Brilinta delivers

Tracy Staton AstraZeneca has so far weathered the Nexium patent cliff well enough to actually raise its full-year sales forecast for 2015. Its Brilinta growth strategy appears to be ...

UPDATED: AstraZeneca scores FDA nod for long-term Brilinta use

Carly Helfand AstraZeneca's blood thinner Brilinta is officially one step closer to living up to the British pharma's $ 3.5 billion ambitions. The FDA has handed down an approval ...

AstraZeneca ties up with little Mirati on another PD-L1 combo trial

John Carroll AstraZeneca's big MedImmune subsidiary has a new partner for its closely-watched PD-L1 checkpoint inhibitor durvalumab (MEDI4736). Little Mirati Therapeutics, which ...

RIP: AstraZeneca clips two pipeline programs in Q2

John Carroll Every quarter AstraZeneca notes at the end of its financial report which of its new drug programs are being discarded and dropped from the pipeline. FierceBiotech News

Clovis boasts promising ovarian cancer responses for AstraZeneca rival rucaparib

John Carroll Over the weekend, Clovis Oncology took another big step toward its near-term goal of launching commercial operations, with plans to take pharma giant AstraZeneca head-on ...
Page 1 of 912345...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS